Request Legal Help Now - Free
LAWSUITS NEWS & LEGAL INFORMATION

Diabetes Drugs Legal News Articles & Interviews

View Lawyer Interviews only

More Type 2 Diabetics add Complaints to Ongoing Onglyza Litigation

More Type 2 Diabetics add Complaints to Ongoing Onglyza Litigation April 4, 2018. By Jane Mundy.
Atlanta, GA: In the past month, two more Onglyza and Kombiglyze lawsuits were filed on behalf of diabetes patients who claim the manufacturer concealed information linking the diabetes drug to an increased risk of heart failure and failed to warn about its alleged potential to cause serious heart problems.
Read [ More Type 2 Diabetics add Complaints to Ongoing Onglyza Litigation ]

Plaintiff Blames Loss of his Lower Leg to Invokana Use

Plaintiff Blames Loss of his Lower Leg to Invokana Use March 21, 2018. By Gordon Gibb.
Trenton, NJ: While a plaintiff having filed a recent Invokana lawsuit makes assertions pertaining to Invokana linked with cardiovascular injuries and kidney failure, it was the amputation of his right leg below the knee less than a year after starting on Invokana that ultimately prompted the plaintiff to move forward with his Invokana side effects lawsuit.
Read [ Plaintiff Blames Loss of his Lower Leg to Invokana Use ]

Deadly Onglyza Side Effects Set in Fast and Lawsuits Lumber On

Deadly Onglyza Side Effects Set in Fast and Lawsuits Lumber On February 25, 2018. By Anne Wallace.
Pittsburgh, PA: Viola Chapman began taking Onglyza and Kombiglyze XR (Saxagliptin) to treat her type 2 diabetes in February 2015. By December, as her Onglyza lawsuit claims, those drugs had caused heart failure, congestive heart failure and cardiovascular injury.
Read [ Deadly Onglyza Side Effects Set in Fast and Lawsuits Lumber On ]

Onglyza Litigation Ramps Up

Onglyza Litigation Ramps Up January 27, 2018. By Jane Mundy.
Miami, FL: Yesterday, The U.S. Judicial Panel on Multidistrict Litigation (JPML) heard from Onglyza and Kombiglyze patients regarding whether to consolidate all federally-filed cases before one court for pre-trial proceedings.
Read [ Onglyza Litigation Ramps Up ]

‘Failure to Warn’ at Heart of Onglyza Lawsuits

‘Failure to Warn’ at Heart of Onglyza Lawsuits December 31, 2017. By Anne Wallace.
San Francisco, CA: Once the procedural wrangling is over, the argument that patients were hurt because drug manufacturers, AstraZeneca and Bristol-Meyers Squibb, failed to warn them of the dangers of Onglyza side effects will be at the heart of the Onglyza lawsuits.
Read [ ‘Failure to Warn’ at Heart of Onglyza Lawsuits ]

Invokana Lawsuits Consolidated into MDL in New Jersey

Invokana Lawsuits Consolidated into MDL in New Jersey November 20, 2017. By Anne Wallace.
Trenton, NJ: The FDA warns of fracture risk with Invokana and Invokamet and more recently of a higher risk for foot and leg amputation. The lawsuit chickens have now come home to roost.
Read [ Invokana Lawsuits Consolidated into MDL in New Jersey ]

Onglyza Lawsuits Seek MDL Status in California

Onglyza Lawsuits Seek MDL Status in California November 4, 2017. By Anne Wallace.
San Francisco, CA: On October 11, 2017, a group of Onglyza plaintiffs filed a Motion to Transfer with the U.S. Judicial Panel on Multidistrict Litigation (JPML). The motion seeks to consolidate the Onglyza lawsuits filed throughout the federal court system in the U.S. District Court for the Northern District of California. At the time of filing, there were 44 lawsuits pending in 24 federal jurisdictions, all of which put forth virtually identical legal and factual theories. Plaintiffs foresee the possibility that hundreds of Onglyza and Kombiglyze (collectively referred to as “Onglyza” in the motion) lawsuits will be filed in the future.
Read [ Onglyza Lawsuits Seek MDL Status in California ]

Add Pancreatic Cancer to Your List of Saxagliptin Worries

Add Pancreatic Cancer to Your List of Saxagliptin Worries October 9, 2017. By Anne Wallace.
Washington, DC: While patient lawsuits have focused on the danger of heart failure as a Saxagliptin side effect, the risk of pancreatic cancer may be flying under the radar. It can be just as deadly, and research suggests a link between Saxagliptin and the disease.
Read [ Add Pancreatic Cancer to Your List of Saxagliptin Worries ]

New Invokana Research (Funded by Manufacturer) Disputes Earlier Studies Showing Amputation Risk

New Invokana Research (Funded by Manufacturer) Disputes Earlier Studies Showing Amputation Risk October 2, 2017. By Jane Mundy.
Washington, DC: Despite exhaustive studies that found an increased risk of amputation among Invokana diabetes patients, Janssen Pharmaceuticals has published its own version of research.
Read [ New Invokana Research (Funded by Manufacturer) Disputes Earlier Studies Showing Amputation Risk ]

Despite Concerns over Onglyza, FDA Keeps Going Back to the Trough

Despite Concerns over Onglyza, FDA Keeps Going Back to the Trough September 6, 2017. By Gordon Gibb.
Washington, DC: In the accepted parlance of the pharmaceutical and medical industries, a drug is considered not unsafe for the intended patient if the benefits of the drug outweigh the risk. One can therefore assume that the US Food and Drug Administration (FDA) took this mantra to heart in 2009 when the federal regulator approved Onglyza (saxagliptin) in spite of reservations over potential saxagliptin side effects and the results of clinical trials associated with Onglyza conducted before the drug was approved.
Read [ Despite Concerns over Onglyza, FDA Keeps Going Back to the Trough ]

Page: 1  2  3  4  5  6     Next»
Request Legal Help Now! - Free